Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks under $50 to invest in. TD Cowen maintained a ...

Roivant Sciences unveiled "exceptional" results Friday for its skin disease treatment, sending the biotech stock flying.

Roivant Sciences has seen its price target narrative tighten up rather than swing wildly, with the model fair value estimate held at US$27.0 per share while the discount rate edges to 7.54% to reflect ...

Roivant Sciences stock: recent performance snapshot Roivant Sciences (ROIV) has drawn fresh attention after a strong recent run, with the share price at $25.82 and positive returns over the past week, ...

Roivant Sciences (ROIV) upgraded to Buy on strong Phase 2 BEACON data for brepocitinib; see pipeline upside, risks, and why it’s timely—read now.

Roivant Sciences (ROIV) is up ~110% in 6 months, but still has no product revenue. Read here for a detailed investment analysis.

As of Friday, February 06, Roivant Sciences Ltd.’s ROIV share price has surged by 17.48%, which has investors questioning if this is right time to sell.

Shares of Roivant Sciences were higher after the company released positive results from a phase-two study of its brepocitinib treatment for cutaneous sarcoidosis, a skin disease. The stock rose 14% to ...

Roivant and Priovant Therapeutics announced positive results from a phase 3 study of brepocitinib. The drug could have blockbuster potential in treating rare and orphan autoimmune diseases. Shares of ...

Tuesday's raiser was Leerink Partners prognosticator David Risinger. Well before market open, he added $1 to his Roivant price target for a new level of $18 per share. In doing so, he maintained his ...